Presentation Title

Analysis of MDM2 Regulation on AURKB Expression in Small Cell Lung Cancer

Presenter Credentials

Karen Kameo, Halmos College of Arts and Sciences, third year, B.S. in Chemistry Alexandra Carbone, Halmos College of Arts and Sciences, third year, B.S. in Biology

Presenter Degree

Degree in Progress

Co-Author Credentials

Thiagarajan Venkatesan, Ph.D., Rumbaugh-Goodwin Institute for Cancer Research, Nova Southeastern University Umamaheswari Natarajan, Ph.D., Rumbaugh-Goodwin Institute for Cancer Research, Nova Southeastern University Katie Crump, Ph.D., Department of Biological Sciences, Nova Southeastern University Appu Rathinavelu, Ph.D., Rumbaugh-Goodwin Institute for Cancer Research, College of Pharmacy, Nova Southeastern University

College

Halmos College of Arts and Sciences and the Guy Harvey Oceanographic Research Center

Campus Location

Ft. Lauderdale

Format

Poster

IRB Approval Verification

N/A

Abstract

Objective. This study was conducted to analyze the molecular mechanism of the MDM2 regulation on AURKB in small cell lung cancer (SCLC). Background. SCLC is one of the most lethal forms of cancer, as it is often metastatic, and currently, there are limited treatment options available for SCLC patients. Therefore, new effective drugs need to be developed against the SCLC to improve the patients’ survival rate. In this study, we focused on the MDM2 and AURKB to develop the treatment strategy against SCLC. Methods. H446 cell line was treated with RG7388, an MDM2 inhibitor, and Barasertib, an AURKB inhibitor, as well as a combination of the two drugs for 24 hrs. In addition, western blots were performed for the MDM2, AURKB, FOXO3a, AKT, p-AKT, and β-actin to determine the impact of RG7388 and Barasertib on H446 cells. The expression level of β-actin was used as a loading control. Results. Our western blot results indicated that there was a down-regulation of MDM2 and AURKB expressions in the RG7388 after 24 hrs of treatment. Also, the level of pAKT expression decreased. Conclusion. The MDM2 inhibition through RG7388 leads to the down-regulation of AURKB expression. Inhibition of AURKB will lead to the onset of cell cycle arrest and consequent cell death. Grants. This study was funded by the PFRDG grant 334877 and the financial support from the Royal Dames of Cancer Research Inc., Ft. Lauderdale, Florida.

Selection Criteria

1

REACH Day 2022 Alex and Karen-020822.pdf (789 kB)
Analysis of MDM2 Regulation on AURKB Expression in Small Cell Lung Cancer

This document is currently not available here.

Share

COinS
 

Analysis of MDM2 Regulation on AURKB Expression in Small Cell Lung Cancer

Objective. This study was conducted to analyze the molecular mechanism of the MDM2 regulation on AURKB in small cell lung cancer (SCLC). Background. SCLC is one of the most lethal forms of cancer, as it is often metastatic, and currently, there are limited treatment options available for SCLC patients. Therefore, new effective drugs need to be developed against the SCLC to improve the patients’ survival rate. In this study, we focused on the MDM2 and AURKB to develop the treatment strategy against SCLC. Methods. H446 cell line was treated with RG7388, an MDM2 inhibitor, and Barasertib, an AURKB inhibitor, as well as a combination of the two drugs for 24 hrs. In addition, western blots were performed for the MDM2, AURKB, FOXO3a, AKT, p-AKT, and β-actin to determine the impact of RG7388 and Barasertib on H446 cells. The expression level of β-actin was used as a loading control. Results. Our western blot results indicated that there was a down-regulation of MDM2 and AURKB expressions in the RG7388 after 24 hrs of treatment. Also, the level of pAKT expression decreased. Conclusion. The MDM2 inhibition through RG7388 leads to the down-regulation of AURKB expression. Inhibition of AURKB will lead to the onset of cell cycle arrest and consequent cell death. Grants. This study was funded by the PFRDG grant 334877 and the financial support from the Royal Dames of Cancer Research Inc., Ft. Lauderdale, Florida.